Skip to content
Evigrade
MinorPsycholeptics. Lithium×Allylamine antifungal (systemic and topical)

Updated · Methodology

Mechanism

Lithium is not metabolised: the kidneys excrete 90–95% of the dose unchanged, so its levels are changed mainly by drugs and conditions that affect kidney function and sodium and fluid balance (lithium SmPC). Terbinafine is metabolised in the liver by at least seven cytochrome P450 enzymes, and its metabolites, which have no antifungal activity, are excreted mainly in the urine. Of these enzymes, it markedly inhibits only CYP2D6 (terbinafine SmPC; terbinafine label, US Food and Drug Administration, FDA). Liver enzymes do not metabolise lithium, so CYP2D6 inhibition does not affect it. Neither terbinafine nor antifungals appear on the lists of drugs that raise or lower lithium levels (lithium SmPC; lithium label, FDA).

Symptoms

The documents describe no symptoms linked to this combination. Lithium toxicity can occur at levels of about 1.5 mEq/L or even lower: first fine tremor, poor coordination and weakness, then drowsiness, ataxia and slurred speech, and in severe cases confusion and seizures (lithium SmPC; lithium label, US Food and Drug Administration, FDA). Terbinafine very commonly causes nausea, diarrhoea and loss of appetite, commonly depression and loss of taste, and rarely liver injury (terbinafine SmPC). Loss of taste can be severe enough for the person to eat less and lose weight (terbinafine label, FDA).

Management

According to the documents, the combination is acceptable, and the doses of lithium and terbinafine need no change. Terbinafine is not one of the drug groups that change lithium levels (lithium SmPC; lithium label, US Food and Drug Administration, FDA). As a general rule for lithium, besides regular monitoring, its level is measured after any change in concurrent medication and during any concomitant illness (lithium label, FDA). With a significant concomitant illness, a concomitant infection or a marked change in salt or fluid intake, monitoring becomes weekly (lithium SmPC). If nausea, vomiting or diarrhoea develop, the lithium dose is monitored carefully and adjusted if needed (lithium SmPC). Check liver function before prescribing terbinafine and repeat the tests after 4–6 weeks of treatment (terbinafine SmPC). Renal function matters for both: lithium and terbinafine are both contraindicated in severe renal impairment, and terbinafine is not recommended with creatinine clearance below 50 mL/min (lithium and terbinafine SmPCs). During terbinafine treatment, watch for depressive symptoms (terbinafine label, FDA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Lithium

Other interactions with Terbinafine